Efficacy and Safety of Arbidol in Treatment of Patients with COVID-19 Infection: A Randomized Clinical Trial

Sara Ghaderkhani
Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences

Arezoo Salami Khaneshan
Department of Infectious Diseases, Imam Khomeini Hospital Complex

Amir Salami (amir.slm1990@gmail.com)
Iran University of Medical Sciences https://orcid.org/0000-0002-4269-3744

Parvaneh Ebrahimi Alavijeh
Department of Infectious Diseases, Imam Khomeini Hospital Complex

Hamid Emadi Kouchak
Department of Infectious Diseases, Imam Khomeini Hospital Complex

Hossein Khalili
Department of Infectious Diseases, Imam Khomeini Hospital Complex

SeyedAhmad SeyedAlinaghi
Department of Infectious Diseases, Imam Khomeini Hospital Complex

Zahra Ahmadinejad
Liver Transplantation Research Center, Department of Infectious Diseases, Imam Khomeini Hospital Complex

Mehmaz Rasolinejad
Department of Infectious Diseases, Imam Khomeini Hospital Complex

Mahboubeh Hajiabdolbaghi
Department of Infectious Diseases, Imam Khomeini Hospital Complex

Sirus Jafari
Department of Infectious Diseases, Imam Khomeini Hospital Complex

Malihe Hasannejad
Department of Infectious Diseases, Imam Khomeini Hospital Complex

Arash Seifi
Department of Infectious Diseases, Imam Khomeini Hospital Complex

Ladan Abasian
Department of Infectious Diseases, Imam Khomeini Hospital Complex

Fereshte Ghiasvand
Liver Transplantation Research Center, Department of Infectious Diseases, Imam Khomeini Hospital Complex

Foroogh Alborzi Avanaki
Imam Khomeini Hospital Complex

Maryam Edalatifard
thoracic research center, Tehran University of Medical Sciences

Mojgan Rahimi
Imam Khomeini Hospital Complex

Research

Keywords: Covid-19, Umifenovir, clinical trial, myalgia, gastrointestinal symptoms, weakness, cough

Posted Date: March 30th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-91430/v3

License: ☺️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at Journal of Iranian Medical Council on August 31st, 2022. See the published version at https://doi.org/10.18502/jimc.v5i2.10468.
Abstract

**Background:** The outbreak of COVID-19 has led to a high demand for finding effective antiviral agents. Preliminary experiments showed that Umifenovir could inhibit coronavirus replication in vivo. There is limited data on the clinical efficacy of COVID-19-infected pneumonia. Therefore, we aimed to evaluate this medication based on clinical findings.

**Methods:** The present study was designed as a clinical trial to investigate the advantages and disadvantages of this medicine compared to empirical treatment. For this purpose, multi-stage sampling was considered. 56 people who have mild to moderate symptoms without signs of sever pneumonia, were selected by accidental non-random sampling method. This sample size was subsequently divided into two groups (group A threated with hydroxychloroquine and group B who threated with combination hydroxychloroquine and Umifenovir) by randomized block sampling (1:1). During the study, three patients left the case group. Their clinical sighns and symptoms were evaluated on 3 th and 7 th and 14 th days after oncet illness while taking these medicines in the disease course. The SPSS software was used for data analysis and the significance level was considered to be $P<0.05$.

**Results:** On the seventh days after visit patients, there were statistically significant differences in recuperation dry cough ($p = 0.001$), weakness ($p = 0.004$), gastrointestinal symptoms ($p = 0.043$) and shortness of breath ($p = 0.001$) between the two groups, so that in patients who under orescription combination HCQ and Umifenovir group had a faster recovery. Generally during illness, there were statistically significantly faster melioration myalgia ($p = 0.03$), gastrointestinal symptoms ($p = 0.047$), and weakness ($p = 0.007$) in patients who threated with both HCQ and Umifenovir.

**Conclusion:** Evaluation clinical findings in mild to moderate COVID-19 patients symptoms and sighns recuperation faster in group who under orescription combination HCQ and Umifenovir regimen. In other words, adding Umifenovir to the empirical treatment accelerated the recovery process of patients’ clinical symptoms.

**Registration:** IR.TUMS.VCR.REC.1399.204, 04.13.2020 , http://ethics.research.ac.ir/IR.TUMS.VCR.REC.1399.204

Introduction

The COVID19 was identified following the epidemic of the “unknown flu virus” that occurred in Wuhan, China(1). The incidence of infection is constantly increasing. The virus can easily be transmitted from one person to another (possibly even by asymptomatic patients) and is currently reported in all countries of the world. This has become a major public health problem(2, 3), with more than 10.5 million people infected (230,211 people in Iran) and more than 512,000 people died (10,958 in iran) so far(4). The prevalence of infection has led to the empirical use of various antiviral therapies in infected patients(5). However, there still seems to be no treatment regimen with specific clinical efficacy and optimal effectiveness.
Umifenovir is a broad-spectrum antiviral drug that has been approved in several countries (6). The antiviral mechanism of this drug is mainly as follows: a) inhibition of the membrane fusion between viral particles and plasma membranes, b) regulation of the immune response by producing interferons and activating macrophages, c) modulation of the expression of inflammatory cytokines such as interleukin-6, interleukin-8, and TNF α (6-8). Recent studies have also shown that Umifenovir has antiviral effects on other viruses such as herpes (9), Zika virus (10), and Ebola virus (11). In the laboratory, the efficacy of Umifenovir in inhibiting severe acute respiratory syndrome (SARS) coronavirus replication has been demonstrated (12, 13), and observational studies have reported the positive effect of this medication on the treatment of COVID-19 (14, 15).

Umifenovir has been used as an anti-influenza drug in various countries for several decades (16, 17). In vitro studies have confirmed the antiviral effect of Umifenovir on coronavirus (12, 13, 16). The innate pathogenesis of the virus leads to mild symptoms in which antiviral therapy can quickly improve the primary symptoms. Then, increased cytokines in the lungs and bone marrow lead to worsening of symptoms of influenza virus or SARS-CoV infections (16, 18-20). Previous data have shown that there are two potential mechanisms involved in the process of lung damage caused by influenza virus, including viral pathogenesis and the host's innate immune responses to the disease (21).

Umifenovir inhibits the viral fusion with the host cell and stimulates the immune system and increases the phagocytic activity of macrophages through interferon production. This drug has a hepatic metabolism and is administered at a dose of 200 mg every 8 hours. The active ingredient of this drug is non-toxic and it rarely causes side effects. (16) Pruritus and skin rashes are among the rare side effects of this medicine and no other serious side effects have been reported. However, it is contraindicated in children under two years of age and pregnant and lactating women. Careful monitoring of its side effects should be done in patients with liver and kidney failures. The LD50 dose of this drug is 4 g/kg body weight (16). Therefore, due to the insufficient number of clinical trials and studies conducted on the treatment of this disease with this drug so far, as well as the lack of specific drug therapy, we aimed to examine the effects of this drug in a more detailed interventional study.

Methodology

Participants

This study is an open-label clinical trial conducted on patients with definitive diagnosis of COVID-19 (PCR testing from nasopharyngeal and oropharyngeal secretions or a clear view on the chest CT scan) (definitive evidence for SARS-CoV-2 in chest CT, Patchy Infiltration apperancece and ground-glass opacities in lungs) who had referred to Imam Khomeini Hospital Complex, Tehran, Iran. This study was conducted from April 20 to June 4, 2020. In this study, multi-stage sampling was considered. In the first stage, 56 people were selected by accidental non-random sampling method. This sample size was subsequently divided into two groups by randomized block sampling (with a randomized block design, the experimenter divides subjects into subgroups called blocks, such that the variability within blocks is
less than the variability between blocks. Then, subjects within each block are randomly assigned to treatment conditions.) (1:1). During the study, three patients left the case group (two patients lost to follow up, one patient discontinued intervention). These two groups included control (N=25) and case (N=28) arms. Their clinical symptoms were examined while taking these medicines in the disease course. (14-day follow-up for each patient). The inclusion criteria for the study were patients with age greater than or equal to 18 years, oral tolerance, and getting written informed consent from the patient and diagnosis of mild to moderate COVID-19 infection (Adolescent or adult with clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) fatigue, anorexia, myalgias and Other non-specific symptoms, such as sore throat, nasal congestion, headache, diarrhoea, nausea and vomiting, have also been reported (1, 22-24) but should be without signs of severe pneumonia (including SpO2 ≥ 90% on room air, respiratory rate > 30 breaths/min; severe respiratory distress) (25)). The exclusion criterion was the patient’s basal Alanine aminotransferase (ALT) value greater than five times the normal range. (Normal value for ALT in blood ranges from 29 to 33 units per liter (IU/L) for males and 19 to 25 IU/L for females)

The case group received hydroxychloroquine (HCQ) at a dose of 200 mg every 12 hours and Umifenovir at a dose of 200 mg every 8 hours for 10 days. The control group received the national treatment protocol proposed for COVID-19 (26), including HCQ every 12 hours for 10 days and acetaminophen and Diphenhydramine oral syrup if needed.

With the exception of Umifenovir, all other standard interventions and treatments were the same for patients in both groups. Umifenovir was provided by the Center for Progress and Development (CPDI) of Iran Presidency and given to the infectious disease ward, and patients did not pay for it. Pharmstandard, one of the leading Russian pharmaceutical companies, is the manufacturer of this drug. Given the open-label nature of the trial, the department of pharmacotherapy was the research supervisor.

**Measurements:**

After obtaining written informed consent from the patients, demographic and clinical characteristics such as age, gender, BMI, history of underlying diseases including COPD, asthma, diabetes mellitus (DM), hypertension, malignancy, HIV, and taking immunosuppressive drugs were extracted and recorded from the patients’ medical history.

In the beginning, factors such as fever, heart rate, respiratory rate, oxygen saturation, and tests such as white blood cell count (WBC), C-reactive protein (CRP), liver enzymes, bilirubin, Creatine phosphokinase (CPK), and electrolytes including sodium, magnesium, and potassium were recorded. Clinical symptoms of patients with COVID-19 infection, such as nausea, vomiting, diarrhea, cough, shortness of breath, fever, body aches, loss of appetite, and other symptoms were also monitored, and changes in symptoms in terms of improvement or worsening were reported on the 3rd day after start treatment in each groups as primary outcome, on the 7th day as secondary outcome, and on the 14th day as the final outcome.
The patients were also monitored for common side effects of Umifenovir, such as skin rashes and gastrointestinal symptoms such as nausea and vomiting, diarrhea or abdominal pain, jaundice, and bradycardia.

**Ethical considerations**

This study was approved by the Ethics Committee of Tehran University of Medical Sciences (TUMS) according to the 2013 Declaration of Helsinki. The written informed consent was obtained from all patients. The patients were informed that they could withdraw from the study at any time and continue their treatment according to the national protocol.

**Statistical analysis**

The Kolmogorov-Smirnov test was first used to assess whether the distribution of variables was normal. Continuous variables were expressed as median (interquartile range (IQR)) and their relationship was reported in the two groups using Mann-Whitney U test and Kruskal–Wallis test. Qualitative variables were expressed as numbers (percentages) and their relationship was analyzed using the Chi-square test and Fisher's exact test. The Kaplan-Meier method was used to compare the improvement in disease symptoms during treatment between the two groups. The statistical analysis was performed using the SPSS software (version 25) and P-values<0.05 were considered statistically significant.
Results

Demographic and clinical characteristics

The statistical population included 53 patients with COVID-19 disease. Among these patients, 25 patients received hydroxychloroquine and 28 patients received a combination of HCQ and Umifenovir. All patients were in the mild to moderate group, and none of them had fever. There were no statistically significant differences in demographic variables such as age, gender, body mass index (BMI), primary symptoms, and patients’ lab tests between the two groups (Tables 1,2,3).
Myalgia was the most common symptom at the onset of the disease, and most of the patients (94.3%) had myalgia upon entering into the study. However, there was no significant difference in the frequency of myalgia between the two groups (P = 0.46).

**Treatment responses**

On the third day of the disease, there were statistically significant differences in myalgia (p = 0.002), dry cough (p = 0.001), weakness (p=0.021), and gastrointestinal symptoms (p=0.001) between the two groups (*Table 4*) and the recovery rate was more in the Umifenovir group. On the seventh day, there were statistically significant differences in dry cough (p = 0.001), weakness (p = 0.004), gastrointestinal symptoms (p = 0.043), and shortness of breath (p = 0.001) between the two groups (*Table 4*) and the recovery rate was more in the Umifenovir group.

In general, according to the Breslow (Generalized Wilcoxon) test and Kaplan-Maier curves (*Figure 1,2,3*) during the disease course, there were statistically significant differences in myalgia (p = 0.03), gastrointestinal symptoms (p = 0.047), and weakness (p = 0.007) between the two groups. However, there were no statistically significant differences in shortness of breath (p = 0.29) and dry cough (P = 0.81) between the two groups during the disease course.

**Side effects**

Umifenovir side effects include dermatitis, gastrointestinal symptoms (such as nausea and diarrhea), jaundice, and neurological symptoms assessed every three days but were not observed in any of the patients after 14 days.

**Discussion**

In this study, patients with mild to moderate disease symptoms (such as myalgia and fatigue) receiving Umifenovir in their treatment regimen recovered more quickly. Given the COVID-19 infection pandemic, there is an urgent need for an effective and specialized antiviral regimen to treat the clinical symptoms of the disease. To this end, due to the limited number of clinical trial studies, we decided to use a medicine that has had favorable primary outcomes in animals as well as case studies. Based on the results of the present study, adding Umifenovir (due to its antiviral and anti-inflammatory effects) to empirical regimens accelerated the recovery process of patients' clinical symptoms.

In the current study, on the third day of the disease, there were statistically significant differences in myalgia, dry cough, weakness, and gastrointestinal symptoms between the two groups, and the recovery rate was better in the Umifenovir group. This means that primary symptoms were controlled in the patients by adding Umifenovir.

In addition to its antiviral mechanism, Umifenovir has potential immunomodulatory and anti-inflammatory effects on the expression of inflammatory cytokines. In vitro studies have shown that pro-inflammatory cytokines such as TNF-α, IL-8, and IL-6 decreased after treatment with Umifenovir(8). Acute
respiratory distress syndrome (ARDS) caused by increased response to inflammatory cytokines/chemokine has also been shown to be one of the main mechanisms of SARS-CoV and MERS-CoV infections(16, 27). It seems that the effects of Umifenovir should be reflected in the secondary symptoms of the disease. In our study, on the seventh day, there were statistically significant differences in dry cough, weakness, gastrointestinal symptoms, and shortness of breath between the two groups, and the group receiving HCQ addition to Umifenovir had a faster recovery.

Another study reported an early improvement in radiological evidence of covid-19 infected pneumonia patients taking Umifenovir. This research also highlighted the antiviral and anti-inflammatory effects of this drug(8). However, another investigation claimed that Umifenovir had no positive effect on clinical and radiological improvement or even virus removal, and that the clinical efficacy of this drug differs from the severity of the disease(16).

Due to this inconsistency in results, the findings of present study demonstrated that gradually there were statistically significant differences in myalgia, gastrointestinal symptoms, and weakness between the case group (Umifenovir) and the control group. This means that with the use of Umifenovir, patients had significantly fewer symptoms over time, confirming that Umifenovir has antiviral and anti-inflammatory effects on this infection.

There were some limitations in this study. First of all, since there is no absolutely effective treatment for this disease, we used empirical treatment along with HCQ for the control group. Second, due to the high cost and a limited number of PCR test kits, we could not use this test to prove the disease and evaluate the response to treatment. Third, due to ethical considerations, the effect of Umifenovir was not assessed individually, so we added Umifenovir to the empirical treatment. Lastly, due to the limited sample size, we may not extrapolate the results to all the patients with Covid-19.

**Conclusion**

In this study, we concluded that the primary symptoms of patients with mild to moderate COVID-19 were controlled by adding Umifenovir to the empirical treatment. This drug had similar effects on secondary symptoms and in most cases, it reduced these symptoms. By using this method, patients significantly recovered faster, confirming that Umifenovir could have antiviral and anti-inflammatory effects. It is also recommended that PCR testing and radiological response be added to patient evaluation in future studies.

**Declarations**

Ethics approval and consent to participate:

This study was approved by the Ethics Committee of Tehran University of Medical Sciences (TUMS) according to the 2013 Declaration of Helsinki (IR.TUMS.VCR.REC.1399.204). The written informed
consent was obtained from all patients. The patients were informed that they could withdraw from the study at any time and continue their treatment according to the national protocol.

Availability of data and material:

Data could be available upon a reasonable request and with the permission of Tehran University of Medical Science ethical committee.

Competing interests:

The authors have no conflict of interest.

Funding:

This research has been supported by Tehran University of Medical Sciences & health services grant.

Authors' contributions:

S.Ghaderkhani, A.Salami, A.salamikhaneshan, SA.AliNaghi contributed to the study conception and design, Data analysis and interpretation, and Critical revision of the article. A.Salami, A.salamikhaneshan, Pebrahimialavijeh, H.EmadiKouchak, H.khalili, Z.Ahmadinejad, M.Rasolinejad, M.Hajiabdolbaghi, S.Jafari, M.Hasannezhad, A.Seifi, L.abasian, f.ghiasvand, F.AlborziAvanaki, M.edalatifard and M.Rahimi conducted the interviews, collect the data and Data analysis. S.Ghaderkhani, A.Salami, wrote and revised the first draft. All authors read and approved the final manuscript.

Consent to publication:

Not applicable.

Acknowledgements:

Authors would like to appreciate the support and constructive comments of the methodologist(s) research development office, Imam khomeini Hospital complex, Tehran, Iran. Also authors thank the staff in the outpatient clinic of Imam khomeini hospital for their support.

Consent to publication:

none

Abbreviations

1. severe acute respiratory syndrome (SARS)
2. Alanine aminotransferase (ALT)
3. hydroxychloroquine (HCQ)
4. Center for Progress and Development of Iran (CPDI)
5. diabetes mellitus (DM)
6. white blood cell count (WBC)
7. C-reactive protein (CRP)
8. Creatine phosphokinase (CPK)
9. Tehran University of Medical Sciences (TUMS)
10. interquartile range (IQR)
11. body mass index (BMI)
12. Acute respiratory distress syndrome (ARDS)

References


Tables

Table 1. Demographic characteristics, symptoms, signs chest CT scan findings in patients on first day visit with Covid-19,
<table>
<thead>
<tr>
<th>Variables</th>
<th>HCQ/Arbidol N (%)</th>
<th>HCQ N (%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>19(67.9)</td>
<td>13(52)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>9(32.1)</td>
<td>12(48)</td>
<td></td>
</tr>
<tr>
<td>Sleep disorders</td>
<td>4(14.3)</td>
<td>5(20)</td>
<td>0.42</td>
</tr>
<tr>
<td>Anosmia</td>
<td>2(7.1)</td>
<td>4(16)</td>
<td>0.28</td>
</tr>
<tr>
<td>Sore throat</td>
<td>13(46.4)</td>
<td>14(56)</td>
<td>0.48</td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>1(3.6)</td>
<td>0</td>
<td>0.53</td>
</tr>
<tr>
<td>Chest CT (Unilateral)</td>
<td>7(25)</td>
<td>12(48)</td>
<td>0.13</td>
</tr>
<tr>
<td>Chest CT (Bilateral)</td>
<td>16(57.1)</td>
<td>11(44)</td>
<td>0.13</td>
</tr>
<tr>
<td>Dry cough</td>
<td>24(85.7)</td>
<td>17(68)</td>
<td>0.12</td>
</tr>
<tr>
<td>Myalgia</td>
<td>27(96.4)</td>
<td>23(92)</td>
<td>0.46</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>22(78.6)</td>
<td>11(44)</td>
<td>0.01</td>
</tr>
<tr>
<td>Gastrointestinal symptoms</td>
<td>8(28.6)</td>
<td>12(48)</td>
<td>0.14</td>
</tr>
<tr>
<td>Weakness</td>
<td>27(96.4)</td>
<td>25(100)</td>
<td>0.53</td>
</tr>
<tr>
<td>Chest pain</td>
<td>5(17.9)</td>
<td>12(48)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

**Table 2.** Laboratory findings of mild to moderate Covid-19 patients on first day, Tehran, 2020
<table>
<thead>
<tr>
<th>Variables</th>
<th>HCQ/Umifenovir (n=28)</th>
<th>HCQ (n=25)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median (IQR) , N (%)</td>
<td>Median (IQR) ,N (%)</td>
<td></td>
</tr>
<tr>
<td>Age (yrs.)</td>
<td>46.5(36-57.5)</td>
<td>42(34-50.5)</td>
<td>0.533</td>
</tr>
<tr>
<td>BMI</td>
<td>25.05(23.75-25.6)</td>
<td>25.23(23.95-26.15)</td>
<td>0.06</td>
</tr>
<tr>
<td>Symptom duration before admission (day)</td>
<td>4(3-5)</td>
<td>4(3-5)</td>
<td>0.97</td>
</tr>
<tr>
<td>RR</td>
<td>22(21-23.75)</td>
<td>22(20-23)</td>
<td>0.351</td>
</tr>
<tr>
<td>PR</td>
<td>99.5(90.25-104.75)</td>
<td>91(86.5-100)</td>
<td>0.16</td>
</tr>
<tr>
<td>O2 saturation (%)</td>
<td>95(94.25-97)</td>
<td>96(95-97)</td>
<td>0.28</td>
</tr>
<tr>
<td>T °C(</td>
<td>37.05(36.9-37.3)</td>
<td>37(36.9-37.5)</td>
<td>0.97</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>16.5(6.75-60)</td>
<td>14(7-29.5)</td>
<td>0.52</td>
</tr>
<tr>
<td>AST (IU/L)</td>
<td>27(18.25-36.25)</td>
<td>25(19.5-30)</td>
<td>0.22</td>
</tr>
<tr>
<td>ALT (IU/L)</td>
<td>27(18.25-36.25)</td>
<td>30(25.5-33)</td>
<td>0.21</td>
</tr>
<tr>
<td>Alk phosphatase (IU/L)</td>
<td>174(150-190.5)</td>
<td>202(170.5-233.5)</td>
<td>0.016</td>
</tr>
<tr>
<td>Cr (mg/dL)</td>
<td>0.95(0.825-1.1)</td>
<td>0.9(0.8-1.05)</td>
<td>0.31</td>
</tr>
<tr>
<td>Troponin (ng/L)</td>
<td>1.5(1.5-2.1)</td>
<td>1.5(1.5-1.5)</td>
<td>0.51</td>
</tr>
<tr>
<td>CPK (mg/dL)</td>
<td>100.5(66.5-156.5)</td>
<td>120(91.5-151)</td>
<td>0.57</td>
</tr>
<tr>
<td>Na (mEq/L)</td>
<td>140(139-141)</td>
<td>141(139-142)</td>
<td>0.15</td>
</tr>
<tr>
<td>K (mEq/L)</td>
<td>4.2(3.925-4.4)</td>
<td>4.1(4-4.2)</td>
<td>0.41</td>
</tr>
<tr>
<td>WBC (10³/µl)</td>
<td>6.6 (5.2-7.652)</td>
<td>5.5 (4.85-6.55)</td>
<td>0.11</td>
</tr>
<tr>
<td>Lymphocytes (10³/µl)</td>
<td>1.674(1.29-2.38)</td>
<td>1.53(1.281-1.874)</td>
<td>0.28</td>
</tr>
<tr>
<td>PLT (10³/µl)</td>
<td>222(180.25-282)</td>
<td>215(199-246.5)</td>
<td>0.87</td>
</tr>
<tr>
<td>Need for hospitalization (yes)</td>
<td>1(3.6)</td>
<td>1(4)</td>
<td>0.98</td>
</tr>
</tbody>
</table>

Table 3. Primary outcome (Survival of symptoms three days after onset illness) and secondary outcome (Survival of symptoms seven days after onset illness) of mild to moderate Covid-19 patients Separately into two study groups, Tehran, 2020
<table>
<thead>
<tr>
<th>Symptoms</th>
<th>HCQ/ Umifenovir N(%)</th>
<th>HCQ N(%)</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myalgia 3\textsuperscript{rd} day</td>
<td>2(7.1)</td>
<td>11(44)</td>
<td>0.002</td>
</tr>
<tr>
<td>7\textsuperscript{th} day</td>
<td>0(0)</td>
<td>1(4)</td>
<td>0.47</td>
</tr>
<tr>
<td>Dry cough 3\textsuperscript{rd} day</td>
<td>21(75)</td>
<td>22(88)</td>
<td>0.001</td>
</tr>
<tr>
<td>7\textsuperscript{th} day</td>
<td>1(3.6)</td>
<td>17(68)</td>
<td>0.001</td>
</tr>
<tr>
<td>Chest pain 3\textsuperscript{rd} day</td>
<td>3(10.7)</td>
<td>12(48)</td>
<td>0.003</td>
</tr>
<tr>
<td>7\textsuperscript{th} day</td>
<td>0(0)</td>
<td>5(20)</td>
<td>0.19</td>
</tr>
<tr>
<td>Weakness 3\textsuperscript{rd} day</td>
<td>7(25)</td>
<td>14(56)</td>
<td>0.021</td>
</tr>
<tr>
<td>7\textsuperscript{th} day</td>
<td>2(7.1)</td>
<td>10(40)</td>
<td>0.004</td>
</tr>
<tr>
<td>Gastrointestinal symptoms 3\textsuperscript{rd} day</td>
<td>0(0)</td>
<td>8(32)</td>
<td>0.001</td>
</tr>
<tr>
<td>7\textsuperscript{th} day</td>
<td>0(0)</td>
<td>4(16)</td>
<td>0.043</td>
</tr>
<tr>
<td>Dyspnea 3\textsuperscript{rd} day</td>
<td>11(29.3)</td>
<td>16(64)</td>
<td>0.072</td>
</tr>
<tr>
<td>7\textsuperscript{th} day</td>
<td>2(7.1)</td>
<td>12(48)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

**Figures**
Figure 1

Kaplan-Meier analysis of recuperation Mialgia between two groups (who threatened with Umifenovir and HCQ and who threatened only HCQ).
Figure 2

Kaplan-Meier analysis of recuperation GI Symptoms between two groups (who threatened with Umifenovir and HCQ and who threatened only HCQ).
Figure 3

Kaplan-Meier analysis of recuperation Weakness between two groups (who threatened with Umifenovir and HCQ and who threatened only HCQ).